Letter

Cancer drugs and copayments

Critical issue is rapidity of review of new drugs

BMJ 2008; 337 doi: 10.1136/bmj.a779 (Published 14 July 2008)
Cite this as: BMJ 2008;337:a779

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Alan Rodger, medical director
  1. 1Beatson West of Scotland Cancer Centre, Glasgow G12 0YN
  1. alan.rodger{at}ggc.scot.nhs.uk

    Baroness Finlay and Lord Crisp support copayments with four essential criteria.1 The fourth criterion will fail as the denominator is described as a small group in the scale of the NHS’s customer base. There is also the assurance that this is “mostly” for drugs yet to be reviewed by the National Institute for Health and Clinical Excellence (NICE).

    That is not the experience revealed by recent high profile cases in the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular